GlassScriptPhysician profile
Benjamin D Renelus
NPI 1760827331
$7,159.28
in general payments reported to CMS, 2019-2025
19 companies · $1,955 in 2025
The $1,955 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $146 · 2021: $1,263 · 2022: $369 · 2023: $432 · 2024: $2,493 · 2025: $1,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $2,413.83 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $1,449.72 | 2021-2025 | General - Hemostasis, Spyglass, Orcapod |
| Abbvie INC. | $1,359.17 | 2019-2025 | |
| Janssen Biotech, INC. | $371.97 | 2021-2025 | Stelara, Tremfya, Remicade |
| Intercept Pharmaceuticals, INC. | $285.55 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.70 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $239.26 | 2022-2025 | Entyvio |
| Apollo Endosurgery US INC | $129.97 | 2021 | |
| Shire North American Group INC | $125.00 | 2019 | |
| Gilead Sciences, INC. | $122.43 | 2019 | |
| Genzyme Corporation | $98.40 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $67.26 | 2023-2024 | Dupixent |
| Madrigal Pharmaceuticals | $58.55 | 2025 | Rezdiffra |
| Olympus America INC. | $53.89 | 2022-2023 | Endoclot Phs |
| Organon LLC | $25.86 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.14 | 2024 | Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $21.12 | 2024 | Exparel, Zilretta, Iovera |
| Pharmacosmos Therapeutics INC. | $20.41 | 2025 | Monoferric |
| Janssen Scientific Affairs, LLC | $14.05 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Renelus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.